Lexaria Bioscience (LEXX) Cash from Financing Activities (2010 - 2026)

Lexaria Bioscience has reported Cash from Financing Activities for 17 years, with the latest figure at $3.0 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 25873.16% year-over-year to $3.0 million in Q1 2026, while the trailing twelve-month figure through May 2026 was $6.5 million (up 7.81% YoY) and the FY2025 annual result came in at $6.0 million, down 41.39% from the prior year.
• Cash from Financing Activities retreated to $3.0 million in Q1 2026 per LEXX's latest filing, from $3.5 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $5.0 million in Q2 2024 and troughed at -$121687.0 in Q3 2023.
• A 5-year average of $1.9 million and a median of $1.7 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities plunged 986.01% in 2023, then soared 25873.16% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$11205.0 in 2022, then soared by 16337.13% to $1.8 million in 2023, then jumped by 138.84% to $4.3 million in 2024, then declined by 20.05% to $3.5 million in 2025, then dropped by 12.38% to $3.0 million in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.0 million, $3.5 million, and $1.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.